Observational studyMedicine2025
A comparative study of different standards of iron supplementation in pregnant women with iron deficiency in plateau area: A retrospective cohort study from a single center in China.
Observational study in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Postpartum Venous Thromboembolism: Altitudinal Gradients, Decadal Trends, and PE-Specific Risk Profiling in Highland Populations.Canadian respiratory journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study investigates the effect of starting iron supplementation with serum ferritin (SF) < 30 μg/L in pregnant women with iron deficiency at Plateau area. This retrospective cohort study included 701 pregnant women with iron deficiency in early pregnancy who delivered in the First People's Hospital of Kunming, China, from January 1, 2022 to July 31, 2023. Iron deficiency was defined as hemoglobin (Hb) ≥ 110 g/L and SF < 30 μg/L during pregnancy. The effect and pregnancy outcome of iron supplementation with SF < 30 μg/L as the standard and Hb < 120 g/L as the standard were compared by statistical methods. Among 701 cases of iron deficiency in the first trimester, 342 cases were given SF < 30 μg/L as the standard of preventive iron supplementation (Group A), and 359 cases were given Hb < 120 g/L as the standard of preventive iron supplementation (Group B). This study found that the Group A had a statistically significant difference in the incidence of anemia and iron deficiency before delivery compared with the Group B (P < .001), and it was found that the Group A had a higher Hb level before delivery (β: 6.693, 95% confidence interval: 5.691-7.696) and those with pre-delivery SF ≥ 30 μg/L had a higher rate of recovery and a faster recovery time (hazard ratio: 10.77, P < .0001). This relationship remained stable after multivariate adjustment using linear regression analysis, and Kaplan-Meier plots of recovery of SF ≥ 30 μg/L during 280 days of gestation also showed significant differences between the 2 groups. In addition, In addition, the incidence of postpartum hemorrhage was significantly lower in the Group A (odds ratio: 0.374, 95% confidence interval: 0.155-0.901), and this association remained stable after adjusting for confounding factors by multivariate binary logistic regression analysis. Other pregnancy outcomes were not statistically significant. In plateau area, pregnant women with iron deficiency who start preventive iron supplementation with SF < 30 μg/L can reduce the incidence of iron deficiency and anemia before delivery compared with those who start preventive iron supplementation with Hb < 120 g/L, improve the level of Hb before delivery and the recovery rate and recovery time of SF ≥ 30 μg/L, and reduce the incidence of postpartum hemorrhage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.